WHO ICTRP trial
Belzutifan/MK-6482 for the treatment of PPGL or pNET or VHL disease
JPRN-jRCT2011220024 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCT2011220024 |
|---|---|
| Public title | Belzutifan/MK-6482 for the treatment of PPGL or pNET or VHL disease |
| Scientific title | A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), or von Hippel-Lindau (VHL) Disease-Associated Tumors |
| Primary sponsor | Hoki Toshifumi |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | United States;Japan;Canada;Japan;Denmark;Japan;France;Japan;Germany;Japan;Hungary;Japan;Israel;Japan;Italy;Japan;Netherlands;Japan;Russia;Japan;Spain;Japan;Sweden;Japan;Turkey;Japan;United… |
| Conditions | Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, VHL Disease-Associated Tumors |
| Interventions | Belzutifan 120 mg, oral, once daily (QD) until progressive disease or discontinuation |
| Registration date | Apr 11, 2022 |
| Target size | 18 |
| Secondary IDs | NCT04924075 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: